TrialJCO precision oncology2024

Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial.

Kieuhoa T Vo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.